--- title: "CNS Pharma | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286411756.md" datetime: "2026-05-14T11:57:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286411756.md) - [en](https://longbridge.com/en/news/286411756.md) - [zh-HK](https://longbridge.com/zh-HK/news/286411756.md) --- # CNS Pharma | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -7.3, missing the estimate of USD -5.37. EBIT: As of FY2026 Q1, the actual value is USD -5.013 M. CNS Pharmaceuticals, Inc. operates as a single segment for performance assessment and operating decisions, with its Chief Executive Officer serving as the Chief Operating Decision Maker (CODM). #### Operational Metrics - **General and Administrative Expense**: For the three months ended March 31, 2026, general and administrative expense was approximately $1,431,000, an increase from approximately $1,095,000 for the comparable period in 2025. This increase was primarily due to increases of approximately $31,000 in advertising and marketing, $315,000 in legal and professional expenses, $99,000 in insurance expense, and $58,000 in other expenses, partially offset by decreases of approximately $52,000 in travel expenses, $49,000 in stock-based compensation, and $66,000 in compensation expense. - **Research and Development Expense**: Research and development expense was approximately $3,544,000 for the three months ended March 31, 2026, compared to approximately $3,243,000 for the comparable period in 2025. This change was mainly attributed to an increase of $240,000 in professional expenses, $61,000 in headcount expenses, and drug manufacturing expenditures for TPI 287, while a decline in Berubicin clinical trial costs offset these increases. - **Loss from Operations**: The company reported a loss from operations of - $4,975,205 for the three months ended March 31, 2026, compared to - $4,337,660 for the same period in 2025. - **Net Loss**: The net loss for the three months ended March 31, 2026, was approximately - $4,937,000, an increase from approximately - $4,301,000 for the comparable period in 2025, primarily due to increased research and development costs and professional expenses. - **Interest Income**: Interest income was $44,270 for the three months ended March 31, 2026, compared to $42,548 for the same period in 2025. - **Interest Expense**: Interest expense was - $6,111 for the three months ended March 31, 2026, compared to - $6,208 for the same period in 2025. - **Stock-based Compensation**: For the three months ended March 31, 2026, stock-based compensation was $2,555, a decrease from $62,367 for the same period in 2025. - **Depreciation**: Depreciation expense was $1,868 for the three months ended March 31, 2026, compared to $1,100 for the same period in 2025. #### Cash Flow - **Net Cash Used in Operating Activities**: Net cash used in operating activities was approximately - $4,649,000 for the three months ended March 31, 2026, compared to approximately - $3,242,000 for the comparable period in 2025. These activities primarily included payments for clinical trial costs, officer compensation, insurance, marketing, and professional fees. - **Net Cash Used in Investing Activities**: Net cash used in investing activities was approximately - $6,000 for the three months ended March 31, 2026, due to the purchase of property and equipment, compared to $0 for the comparable period in 2025. - **Net Cash Provided by Financing Activities**: Net cash provided by financing activities was approximately $405,000 for the three months ended March 31, 2026, primarily from common stock sales, partially offset by notes payable repayments. For the comparable period in 2025, net cash provided was approximately $9,828,000, also from common stock sales, partially offset by notes payable repayments. #### Unique Metrics - **Cash and Cash Equivalents**: As of March 31, 2026, cash and cash equivalents were $2,950,877, a decrease from $7,201,014 as of December 31, 2025. - **Total Assets**: Total assets were $4,653,192 as of March 31, 2026, down from $8,623,466 as of December 31, 2025. - **Total Liabilities**: Total liabilities were $4,582,487 as of March 31, 2026, up from $4,100,910 as of December 31, 2025. - **Accumulated Deficit**: The accumulated deficit increased to - $105,212,314 as of March 31, 2026, from - $100,275,268 as of December 31, 2025. - **Common Stock Issued**: During the three months ended March 31, 2026, CNS Pharmaceuticals, Inc. sold 178,933 shares of common stock through the AGP ATM Sales Agreement for net proceeds of approximately $501,000. As of March 31, 2026, the company had sold a total of 447,102 shares for net proceeds of approximately $23.7 million under this agreement. - **Private Placement Financing**: Subsequent to March 31, 2026, on May 4, 2026, CNS Pharmaceuticals, Inc. completed a private placement financing, resulting in gross proceeds of approximately $22.5 million. #### Future Outlook and Strategy CNS Pharmaceuticals, Inc. announced a new corporate strategy in March 2026, focusing on developing innovative therapies for serious diseases by leveraging its executive team’s multi-functional experiences across high-value therapeutic areas. This strategy includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets TPI 287 and Berubicin. The company estimates that the proceeds from the May 2026 private placement, combined with existing cash, will be sufficient to fund operations beyond twelve months from the issuance of these financial statements, though significant additional capital will be required for drug candidate development. ### Related Stocks - [CNSP.US](https://longbridge.com/en/quote/CNSP.US.md) ## Related News & Research - [CNS Pharmaceuticals Announces Private Placement and Board Changes](https://longbridge.com/en/news/285064548.md) - [LG CNS Expands North American AX Business, Supporting Smart Factory Transformation for SMEs](https://longbridge.com/en/news/286971453.md) - [Cohen & Steers Income Opportunities REIT, Inc. Acquires Shopping Center in Charlotte, North Carolina | CNS Stock News](https://longbridge.com/en/news/286263946.md) - [Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device](https://longbridge.com/en/news/286915159.md) - [Innate Pharma reports Q1 results](https://longbridge.com/en/news/286225966.md)